tiprankstipranks
Advertisement
Advertisement

BAYRY Stock Latest News

Bayer Targets Atrial Fibrillation With New Phase 2 Rhythm Drug: What Investors Should Watch
Company AnnouncementsBayer Targets Atrial Fibrillation With New Phase 2 Rhythm Drug: What Investors Should Watch
5h ago
BAYRY
Bayer announces new investigational data from Kerendia’s Phase III trial
PremiumThe Fly
Bayer announces new investigational data from Kerendia’s Phase III trial
2d ago
Bayer announces Phase II Aracog trial met primary endpoint
PremiumThe Fly
Bayer announces Phase II Aracog trial met primary endpoint
4d ago
Bayer assumed with a Hold at Jefferies
PremiumThe Fly
Bayer assumed with a Hold at Jefferies
6d ago
Evogene price target lowered to $2.15 from $2.25 at Alliance Global
PremiumThe Fly
Evogene price target lowered to $2.15 from $2.25 at Alliance Global
9d ago
EVGN
Olema Oncology announces collaboration, supply agreement with Bayer
PremiumThe FlyOlema Oncology announces collaboration, supply agreement with Bayer
9d ago
OLMA
Bayer to present new data across oncology portfolio
Premium
The Fly
Bayer to present new data across oncology portfolio
14d ago
Bayer announces Priority Review designation for Kerendia
Premium
The Fly
Bayer announces Priority Review designation for Kerendia
14d ago
Bayer upgraded to Buy from Hold at DZ Bank
PremiumThe Fly
Bayer upgraded to Buy from Hold at DZ Bank
16d ago
Bayer Tests Digital Heart Monitoring With ACO-Monitor: What Investors Should Watch
PremiumCompany Announcements
Bayer Tests Digital Heart Monitoring With ACO-Monitor: What Investors Should Watch
16d ago
BAYRY
Bayer granted priority review for asundexian by FDA
PremiumThe Fly
Bayer granted priority review for asundexian by FDA
17d ago
Bayer Advances KRAS G12D Colorectal Cancer Study With New BAY 3771249 Trial
PremiumCompany Announcements
Bayer Advances KRAS G12D Colorectal Cancer Study With New BAY 3771249 Trial
17d ago
BAYRY
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
PremiumThe FlyBayer announces HYRNUO sNDA granted Priority Review status by FDA
17d ago
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
Premium
The Fly
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
17d ago
REGN
Bayer announces presentation of new Phase II ARASEC data on NUBEQA
Premium
The Fly
Bayer announces presentation of new Phase II ARASEC data on NUBEQA
20d ago
Bayer Targets China Prostate Cancer Market With New Darolutamide Real‑World Study
PremiumCompany Announcements
Bayer Targets China Prostate Cancer Market With New Darolutamide Real‑World Study
20d ago
BAYRY
Bayer launches 2026 campaign to expand food access with Luke Bryan
PremiumThe Fly
Bayer launches 2026 campaign to expand food access with Luke Bryan
22d ago
Midday Fly By: eBay rejects GameStop offer, Trian said to eye Wendy’s bid
PremiumThe Fly
Midday Fly By: eBay rejects GameStop offer, Trian said to eye Wendy’s bid
23d ago
Q
BA
Bayer raises FY26 sales view to EUR 44.5B-EUR 46.5B from EUR 44B-EUR 46B
PremiumThe Fly
Bayer raises FY26 sales view to EUR 44.5B-EUR 46.5B from EUR 44B-EUR 46B
23d ago
Bayer reports Q1 core EPS EUR 2.71 vs. EUR 2.40 last year
PremiumThe FlyBayer reports Q1 core EPS EUR 2.71 vs. EUR 2.40 last year
23d ago
BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026
Premium
The Fly
BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026
24d ago
BBIO
The Week That Was, The Week Ahead: Macro and Markets, May 10
Premium
Market News
The Week That Was, The Week Ahead: Macro and Markets, May 10
26d ago
F
V

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >